On 29 March 2018, Suzhou Kintor Pharma announced the appointment of Mr. Huang Yuqing (Eugene) as company’s CFO, responsible for the company’s capital market strategy, business development cooperation and corporate finance.
Mr. Huang has many years of experience in capital markets and healthcare investment, especially in the medical industry, including securities analysis, investment and financing, and financial business development. Prior to joining Kintor Pharma, he served as Lead China Healthcare Analyst at Jefferies, and ranked third place in “Institutional Investor (II)” All-China (International) Survey in 2017. Prior to joining Jefferies, Mr. Huang is engaged in pharmaceutical-related investment work at many international investment banks such as CLSA and well-known healthcare-related funds.
Kintor Pharma is an innovative drug R&D company based in China and expanding around the world. The company focuses on the three major cancers, namely prostate cancer, breast cancer and liver cancer that lack effective treatment method and account for 50% of the cancer population. The company has multiple products in the pipeline at different product stages. Dr. Tong Youzhi, Founder and CEO of Kintor Pharma said: “We sincerely welcome Mr. Huang to join Kintor Pharma. Mr. Huang’s experience in the capital market, business development and corporate finance will help us face the opportunities and challenges of the capital market, and improve and strengthen the company’s management team.”